Histone deacetylase inhibitors: New treatment options for inflammatory joint disease?

Joint Bone Spine

Volumn 77, Issue 5, 2010, Pages 395-398

  Toussirot, Éric ^a,b,c   Khan, Kashif Aziz ^b,c   Bertolini, Ewa ^a   Wendling, Daniel ^a,b   Herbein, Georges ^b,c  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c HÔPITAL SAINT JACQUES   (France)

Author keywords

Gene regulation; Histone acetylase; Histone deacetylase inhibitors

Indexed keywords

4 N ACETYLDINALINE; ADJUVANT; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; GLUCOCORTICOID; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PHENYLACETIC ACID; PYROXAMIDE; ROMIDEPSIN; SIRTINOL; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ASTHMA; BONE INJURY; CARTILAGE; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLLAGEN INDUCED ARTHRITIS; DRUG DESIGN; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; ENTERITIS; HUMAN; LOW DRUG DOSE; NONHUMAN; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYMPTOM; SYNOVITIS; SYNOVIUM; T CELL LYMPHOMA; TREATMENT INDICATION;

ANIMALS; ARTHRITIS, RHEUMATOID; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HUMANS; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 77957886100     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.03.009     Document Type: Short Survey

References (37)

1. Fautrel B., Pham T., Mouterde G., et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007, 74:627-637.
2. Senolt L., Vencovský J., Pavelka K., et al. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9:102-107.
3. Lioté F. Cytokines et voies de signalisation cellulaire au cours de la polyarthrite rhumatoïde. Rev Rhum 2002, 69(Suppl. 5):206-212.
4. Morel J., Berenbaum F. Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine 2004, 71:503-510.
5. Rosato R.R., Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin Invest Drugs 2004, 13:21-38.
6. Blanchard F., Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov Today 2005, 10:197-204.
7. Glaser K.B. HDAC inhibitors: clinical update and mechanism based potential. Bioch Pharmacol 2007, 74:659-671.
8. Halili M.A., Andrews M.R., Sweet M.J., et al. Histone deacetylase in inflammatory disease. Curr Top Med Chem 2009, 9:309-319.
9. Grabiec A.M., Tak P.P., Reedquist K.A. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HAT on?. Arthritis Res Ther 2008, 10:226. [Epub 2008 Oct 17].
10. Cherrier T., Suzanne S., Redel L., et al. p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene 2009, 28:3380-3389.
11. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydoxyamic acid SAHA) for refractory cutaneous T cell lymphoma. Blood 2007, 109:31-39.
12. Yin L., Laevsky G., Giardina C. Butyrate suppression of colonocyte NFκB activation and cellular proteasome activity. J Biol Chem 2001, 276:44641-44646.
13. Segain J.P., Raingeard de la Blétière D., Bourreille A., et al. Butyrate inhibits inflammatory response through NFκB inhibition: implications for Crohn's disease. Gut 2000, 47:397-403.
14. Ashburner B.P., Westerheide S.D., Bladwin A.S. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001, 21:7065-7077.
15. Imre G., Gekeler V., Leja A., et al. Histone deacetylase inhibitors suppress the inducibility of nuclear factor κB by tumor necrosis factor α receptor 1 down regulation. Cancer Res 2006, 66:5409-5418.
16. Viatour P., Legrand-Poels S., Van Lint C., et al. Cytoplasmic IkappaBalpha increases NF-kappa B-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3. J Biol Chem 2003, 278:46541-46548.
17. Mahlknecht U., Will J., Hoelzer D., et al. Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol 2004, 173:3979-3990.
18. Leoni F., Zaliani A., Bertolini G., et al. The anti tumor histone deacetylase inhibitor suberoylanilide hydroxyamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 2002, 99:2995-3000.
19. Wang L., Tao R., Hancock W.W. Using histone deacetylase inhibitors to enhance Foxp3+ regulatory T cell function and induce allograft tolerance. Immunol Cell Biol 2009, 87:195-202.
20. Su R.C., Becker A.B., Kozyrskyj A.L., et al. Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J Allergy Clin Immunol 2008, 121:57-63.
21. Brogdon J.L., Xu Y., Szabo S.J., et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
22. Kwon H.Y., Kim M.S., Nakajima H., et al. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002, 97:290-296.
23. Ito K., Yamamura S., Essilfie-Quaye S., et al. Histone deacetylase 2- mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med 2006, 203:7-13.
24. Chung Y.L., Lee M.Y., Wang A.J., et al. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003, 8:707-717.
25. Nakamura T., Kukita T., Shobuike T., et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production. J Immunol 2005, 175:5809-5816.
26. WAFF1/Cip1 expression. Arthritis Rheum 2004, 50:3365-3376.
27. Lin H.S., Hu C.Y., Chan H.Y., et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen induced arthritis in rodents. Br J Pharmacol 2007, 150:862-872.
28. Nasu Y., Nishida K., Miyazawa S., et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody induced arthritis mouse model. Osteoarthritis Cart 2008, 16:723-732.
29. Saouaf S.J., Li B., Zhang G., et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen induced arthritis. Exp Mol Pathol 2009, 87:99-104.
30. Huber L., Brock M., Hemmatazad H., et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid and osteoarthritis patients. Arthritis Rheum 2007, 56:1087-1093.
31. Horiuchi M., Morinobu A., Chin T., et al. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009, 36:1580-1589.
32. Young D.A., Lakey R.L., Pennington C.J., et al. Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 2005, 7:R503-R512.
33. Chabane N., Zayed N., Afif H., et al. Histone deacetylase inhibitors suppress interleukin 1β induced nitric oxide and prostaglandin E2 production in human chondrocytes. Osteoarthritis Cartilage 2008, 16:1267-1274.
34. Yi T., Baek J.H., Kim H.J., et al. Trichostatin A mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis. Exp Mol Med 2007, 39:213-221.
35. Cosio B.G., Mann B., Ito K., et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma. Am J Respir Crit Care Med 2004, 170:141-147.
36. Reynolds P.R., Cosio M.G., Hoidal J.R. Cigarette smoke-induced Egr-1 upregulates proinflammatory cytokines in pulmonary epithelial cells. Am J Respir Cell Mol Biol 2006, 35:314-319.
37. Choo Q.Y., Ho P.C., Lin H.S. Histone deacetylase inhibitors: new hope for rheumatoid arthritis?. Curr Pharm Des 2008, 14:803-820.